Reply: Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis?

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 7, 2012, Pages 693-694

  Noth, Imre ^a   Olman, Mitchell ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PREDNISOLONE; PROTEINASE INHIBITOR; WARFARIN;

ACUTE LUNG INJURY; ANTICOAGULANT THERAPY; DRUG SELF ADMINISTRATION; EXERCISE; FIBROGENESIS; HUMAN; IDIOPATHIC DISEASE; LETTER; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG FUNCTION; LUNG GAS EXCHANGE; MORTALITY; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; SARCOIDOSIS; SURVIVAL; UPREGULATION;

EID: 84867125315     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.186.7.693a     Document Type: Letter

References (9)

1. Noth I, Anstrom K, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:88-95.
2. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-1482. (Pubitemid 41324435)
3. Gunther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, Morr H, Grimminger F, Walmrath D, Seeger W. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000;83:853-886.
4. Wygrecka M, Kwapiszewska G, Jablonska E, von Gerlach S, Henneke I, Zakrzewicz D, Guenther A, Preissner KT, Markart P. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:1703-1714.
5. Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009;119:2550-2563.
6. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005;280:17286-17293. (Pubitemid 41389197)
7. Fryer A, Huang YC, Rao G, Jacoby D, Mancilla E, Whorton R, Piantadosi CA, Kennedy T, Hoidal J. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung 1,2. J Pharmacol Exp Ther 1997;282:208-219. (Pubitemid 27425543)
8. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins: implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998;101:877-889. (Pubitemid 28096085)
9. Garg HG, Thompson BT, Hales CA. Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000;279:L779-L789.